CGON - CG Oncology Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $83.25 DETAILS

Stock News

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer

Jul 27, 2026 02:45 PM • globenewswire.com

CG Oncology Stock Gains 12% in Three Months: What's Driving It?

CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.

Jul 13, 2026 06:07 AM • zacks.com

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead

CG Oncology NASDAQ: CGON Chief Executive Officer Arthur outlined the company's upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthcare Conference, emphasizing data readouts, a potential filing and commercial preparation in non-muscle invasive bladder cancer, or NMIBC.

Jun 09, 2026 11:02 PM • marketbeat.com

CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Jun 09, 2026 01:52 PM • seekingalpha.com

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

CG Oncology NASDAQ: CGON is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healthcare Conference in New York.

Jun 07, 2026 01:06 PM • marketbeat.com

CG Oncology to Present at Upcoming Investor Conferences in June

DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows:

May 28, 2026 12:05 PM • globenewswire.com

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

CG Oncology NASDAQ: CGON executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company's investigational therapy for non-muscle invasive bladder cancer, and to discuss upcoming regulatory, manufacturing and commercial milestones.

May 20, 2026 06:05 PM • marketbeat.com

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Last year's awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the recipients of the second annual CG-SUO-CTC NMIBC Research Fellowship designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

May 19, 2026 04:00 AM • globenewswire.com

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively

May 15, 2026 04:00 AM • globenewswire.com

CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears

CG Oncology NASDAQ: CGON executives said the company remains on track to complete a rolling biologics license application for cretostimogene in BCG-unresponsive high-risk non-muscle invasive bladder cancer by the fourth quarter, while reiterating expectations for top-line data from a separate Phase 3 trial in the first half of the year.

May 14, 2026 11:09 PM • marketbeat.com

CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 12, 2026 12:21 PM • seekingalpha.com

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-

May 11, 2026 12:15 PM • globenewswire.com

CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings

CG Oncology (NASDAQ:CGON) reported mixed results for the first quarter on Friday.

May 11, 2026 08:40 AM • benzinga.com

CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates

CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to a loss of $0.45 per share a year ago.

May 08, 2026 06:36 AM • zacks.com

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the first quarter ended March 31, 2026, and provided business updates.

May 08, 2026 04:30 AM • globenewswire.com

Wall Street Analysts Think CG Oncology, Inc. (CGON) Could Surge 29.78%: Read This Before Placing a Bet

The consensus price target hints at a 29.8% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

May 05, 2026 06:55 AM • zacks.com

CG Oncology to Present at Upcoming Investor Conferences in May

DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will participate in fireside chat presentations at the Bank of America Health Care Conference and the RBC Capital Markets Global Healthcare Conference this month. The details of the upcoming events are as follows: Bank of America Health Care Conference 2026 Date: Tuesday, May 12, 2026Presentation Time: 10:40 AM – 11:10 AM PTLocation: Las Vegas, NV RBC Capital Markets Global Healthcare Conference Date: Wednesday, May 20, 2026Presentation Time: 2:35 PM – 3:00 PM ETLocation: New York, NY Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company's website at www.cgoncology.com.

May 05, 2026 04:00 AM • globenewswire.com

CG Oncology, Inc. (CGON) Upgraded to Buy: Here's What You Should Know

CG Oncology, Inc. (CGON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

May 01, 2026 09:02 AM • zacks.com

CGON Stock Up 60.8% in Six Months: Here's What You Need to Know

CG Oncology stock surges as early phase III data, strong bladder cancer results and a $900M cash cushion fuel rising investor confidence.

Apr 15, 2026 07:10 AM • zacks.com

CG Oncology, Inc. $CGON Stake Lifted by JPMorgan Chase & Co.

JPMorgan Chase and Co. boosted its stake in CG Oncology, Inc. (NASDAQ: CGON) by 321.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 227,879 shares of the company's stock after buying an additional 173,785 shares during the period. JPMorgan

Mar 30, 2026 01:13 AM • defenseworld.net

Price Targets

CGON - CG Oncology Inc.

Stock News

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

CG Oncology Stock Gains 12% in Three Months: What's Driving It?

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead

CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

CG Oncology to Present at Upcoming Investor Conferences in June

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears

CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings

CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

Wall Street Analysts Think CG Oncology, Inc. (CGON) Could Surge 29.78%: Read This Before Placing a Bet

CG Oncology to Present at Upcoming Investor Conferences in May

CG Oncology, Inc. (CGON) Upgraded to Buy: Here's What You Should Know

CGON Stock Up 60.8% in Six Months: Here's What You Need to Know

CG Oncology, Inc. $CGON Stake Lifted by JPMorgan Chase & Co.

Price Targets

CG Oncology price target raised to $82 from $77 at Truist

CG Oncology price target raised to $81 from $79 at RBC Capital

CG Oncology price target raised to $80 from $77 at Wedbush

CG Oncology price target raised to $79 from $73 at RBC Capital

CG Oncology price target raised to $90 from $60 at UBS

CG Oncology price target raised to $75 from $66 at Truist

CG Oncology price target raised to $73 from $61 at RBC Capital

CG Oncology price target raised to $70 from $55 at Piper Sandler

CG Oncology price target raised to $82 from $55 at Goldman Sachs

CG Oncology price target raised to $93 from $89 at Morgan Stanley

CG Oncology price target raised to $66 from $62 at Truist

CG Oncology price target raised to $89 from $82 at Morgan Stanley

CG Oncology initiated with an Outperform at Wedbush

CG Oncology initiated with a Buy at Truist

CG Oncology price target raised to $61 from $53 at RBC Capital

CG Oncology initiated with a Buy at Guggenheim

CG Oncology price target raised to $79 from $56 at Morgan Stanley

CG Oncology initiated with an Overweight at Piper Sandler

CG Oncology assumed with an Overweight at Morgan Stanley

UBS Starts CG Oncology (CGON) at Buy